Jump to main content
Jump to site search

Issue 34, 2018
Previous Article Next Article

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Author affiliations

Abstract

Mitoxantrone (MTO) is a topoisomerase II inhibitor which has been used to treat various forms of cancer either as a solo chemotherapy regimen or as a component in cocktail treatments. However, as with other anti-neoplastic agents, MTO has severe cardiac side effects. Therefore, a drug delivery approach holds promise to improve the safety and applicability of this chemotherapy. Here, we report the application of a plant virus-based nanotechnology derived from tobacco mosaic virus (TMV) as a delivery vehicle for MTO towards cancer therapy. TMV is a high aspect-ratio, soft-matter nanotube with dimensions of 300 × 18 nm and a 4 nm wide channel. The surface chemistry of the interior and exterior TMV surfaces is distinct and we established charge-driven drug loading strategies to encapsulate therapeutics for drug delivery. We demonstrate effective MTO loading into TMV yielding ∼1000 MTO per TMV carrier. The treatment efficacy of MTO-loaded TMV (MTOTMV) was assessed in in vitro and in vivo models. In vitro testing confirmed that MTO maintained its efficacy when delivered by TMV in a panel of cancer cell lines. Drug delivery in vivo using a mouse model of triple negative breast cancer demonstrated the superior efficacy of TMV-delivered MTO vs. free MTO. This study demonstrates the potential of plant virus-based nanotechnology for cancer therapy and drug delivery.

Graphical abstract: Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Back to tab navigation

Article information


Submitted
22 May 2018
Accepted
27 Jul 2018
First published
21 Aug 2018

Nanoscale, 2018,10, 16307-16313
Article type
Paper

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

R. D. Lin and N. F. Steinmetz, Nanoscale, 2018, 10, 16307
DOI: 10.1039/C8NR04142C

Social activity

Search articles by author

Spotlight

Advertisements